Equities Analysts Offer Predictions for BRNS FY2024 Earnings

Barinthus Biotherapeutics plc (NASDAQ:BRNS) – HC Wainwright raised their FY2024 EPS estimates for shares of Barinthus Biotherapeutics in a research report issued on Monday, January 13th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($1.32) per share for the year, up from their previous estimate of ($1.59). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Barinthus Biotherapeutics’ current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for Barinthus Biotherapeutics’ Q4 2024 earnings at ($0.29) EPS, Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.27) EPS and FY2025 earnings at ($1.09) EPS.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The company had revenue of $14.97 million during the quarter. During the same period in the previous year, the business posted ($0.37) earnings per share.

Barinthus Biotherapeutics Stock Performance

Barinthus Biotherapeutics stock opened at $0.95 on Wednesday. The company has a market capitalization of $38.12 million, a P/E ratio of -0.64 and a beta of -0.81. Barinthus Biotherapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $4.16. The stock has a 50-day simple moving average of $1.07 and a 200-day simple moving average of $1.24.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.